NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board
Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.
Credit: RLT Images
While most scientists look at Covid-19 as a viral respiratory illness, Nir Barzilai takes a slightly different perspective. Instead Barzilai, founder of the Institute of Ageing Research at the Albert Einstein College of Medicine in New York, sees it as a disease of ageing.
The grim statistics show that he has a point. In Europe, people over 60 have accounted for 90% of fatalities since the start of August. While the impact of Covid-19 has been universal, older people have been disproportionally affected.
“This virus has no eyes, but it could see immediately who is old and more vulnerable,” says Barzilai.
For Barzilai and other geroscientists - scientists who study the biology of ageing - this represents an opportunity. They have long argued that we need a different perspective for tackling many chronic diseases, from cancer to Alzheimer s. As all of these illnesses become more common with age, geroscientists have suggested that therapies attempting to reverse some of the cellular mechanisms of ageing might make older individuals more resilient to a whole range of diseases. The premise of this approach is that while we typically measure age chronologically, the number of years we have been alive, your biological age says far more about your health. Biological age is indicated through various biomarkers ranging from the length of telomeres - the tips of chromosomes - to changes in DNA expression, and even your gut microbiome.
Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer s Disease International Conference Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer s Disease by Identifying Patients Early in the Disease Process
News provided by
Share this article
Share this article
MILAN, Dec. 11, 2020 /PRNewswire/ Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker test at the 34
th Annual Conference of Alzheimer s Disease International (ADI). Diadem presented early clinical data for its AlzoSure
® Predict assay in the Symposium, outlined initial commercialization plans and hosted an expert panel. To view a replay of the Symposium, click here